Theravance Biopharma Ownership | Who Owns Theravance Biopharma?


OverviewForecastRevenueFinancialsChartTranscripts

Theravance Biopharma Ownership Summary


Theravance Biopharma is owned by 94.15% institutional investors, 4.68% insiders, and 1.17% retail investors. Madison avenue partners, lp is the largest institutional shareholder, holding 17.96% of TBPH shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.50% of its assets in Theravance Biopharma shares.

TBPH Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTheravance Biopharma94.15%4.68%1.17%
SectorHealthcare Stocks 50.62%12.41%36.97%
IndustryBiotech Stocks 49.15%12.15%38.70%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Madison avenue partners, lp9.21M17.96%$156.61M
Weiss asset management lp7.46M14.54%$126.77M
Blackrock funding, inc. /de4.56M8.90%$77.56M
Blackrock3.78M7.83%$32.06M
Newtyn management3.43M6.70%$58.38M
Irenic capital management lp2.76M5.38%$46.94M
Vanguard group2.37M4.69%$44.29M
Vanguard capital management1.77M3.45%$30.12M
State street1.33M2.59%$22.59M
Two sigma investments, lp1.23M2.39%$20.83M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Newtyn management3.43M7.29%$58.38M
Madison avenue partners, lp9.21M6.74%$156.61M
Irenic capital management lp2.76M2.25%$46.94M
Rangeley capital99.50K1.55%$1.69M
Weiss asset management lp7.46M1.33%$126.77M
Oasis management583.49K0.53%$9.92M
Cannon global investment management10.32K0.50%$175.46K
Jackson creek investment advisors85.51K0.48%$1.44M
Camber capital management lp450.00K0.47%$4.96M
Nverses capital14.77K0.39%$251.12K

Top Buyers

HolderShares% AssetsChange
Mackenzie financial985.85K0.02%737.17K
Citadel advisors506.67K0.00%420.58K
Sixth street partners management company321.15K0.00%321.15K
Glazer capital301.83K0.13%301.83K
Blackrock funding, inc. /de4.56M0.00%266.20K

Top Sellers

HolderShares% AssetsChange
Baupost group llc/ma---4.20M
Newtyn management3.43M7.29%-1.41M
Pictet asset management sa---684.89K
Camber capital management lp450.00K0.47%-550.00K
Blackrock3.78M0.00%-428.18K

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company321.15K0.00%321.15K$5.46M
Glazer capital301.83K0.13%301.83K$5.13M
Algert global199.71K0.05%199.71K$2.92M
Caption management163.70K0.02%163.70K$2.66M
Wedge capital management l l p/nc128.84K0.04%128.84K$2.19M

Sold Out

HolderChange
Sbi securities-2.00
True wealth design-2.00
Capital performance advisors llp-5.00
Wealthspire advisors-12.00
Nelson, van denburg & campbell wealth management group-13.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20261821.68%48,280,263-3.63%940.99%100-5210.64%
Mar 31, 20261720.58%46,814,907-5.60%930.97%97-2.02%45-4.26%
Dec 31, 202588-47.31%16,063,224-66.80%310.34%45-47.67%29-27.50%
Sep 30, 202570-48.53%10,629,292-77.11%210.24%37-52.56%14-56.25%
Jun 30, 20251352.27%46,426,0143.43%931.15%7732.76%32-31.91%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.30M2.50%-29.00K
Vanguard Morn Total Stk Mkt Idx Investor1.30M2.50%-29.00K
Vanguard MStar Total Stk Mkt Idx Invest1.30M2.50%-
Vanguard US Total Market Shares ETF1.07M2.15%-
iShares Russell 2000 ETF1.03M1.98%-18.24K
Pictet Biopharmaceutical Mother652.30K1.32%-349.81K
Vanguard Institutional Extnd Mkt Idx Tr436.47K0.84%818.00
Fidelity Small Cap Index381.00K0.74%853.00
Invesco Biotechnology & Genome ETF366.33K0.71%-
iShares Biotechnology ETF350.75K0.68%-1.07K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 01, 2026Samaha Eli-Sell$642.63K
Jun 29, 2026Samaha Eli-Sell$4.72M
Jun 30, 2026Samaha Eli-Sell$428.79K
Jun 15, 2026Farnum Rhonda SVP, COMM & MEDICAL AFFAIRSSell$54.53K
Jun 15, 2026Farnum Rhonda SVP, COMM & MEDICAL AFFAIRSSell$54.56K

Insider Transactions Trends


DateBuySell
2026 Q2-3
2026 Q1-3
2025 Q4-11
2025 Q3-3
2025 Q2-2

TBPH Ownership FAQ


Who Owns Theravance Biopharma?

Theravance Biopharma shareholders are primarily institutional investors at 94.15%, followed by 4.68% insiders and 1.17% retail investors. The average institutional ownership in Theravance Biopharma's industry, Biotech Stocks , is 49.15%, which Theravance Biopharma exceeds.

Who owns the most shares of Theravance Biopharma?

Theravance Biopharma’s largest shareholders are Madison avenue partners, lp (9.21M shares, 17.96%), Weiss asset management lp (7.46M shares, 14.54%), and Blackrock funding, inc. /de (4.56M shares, 8.90%). Together, they hold 41.40% of Theravance Biopharma’s total shares outstanding.

Does Blackrock own Theravance Biopharma?

Yes, BlackRock owns 7.83% of Theravance Biopharma, totaling 3.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.06M$. In the last quarter, BlackRock decreased its holdings by -428K shares, a -10.17% change.

Who is Theravance Biopharma’s biggest shareholder by percentage of total assets invested?

Newtyn management is Theravance Biopharma’s biggest shareholder by percentage of total assets invested, with 7.29% of its assets in 3.43M Theravance Biopharma shares, valued at 58.38M$.

Who is the top mutual fund holder of Theravance Biopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Theravance Biopharma shares, with 2.50% of its total shares outstanding invested in 1.3M Theravance Biopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools